NXP200 Wins Breakthrough Therapy Designation in China for High-Grade Glioma
NVCT has more than doubled off its 52-week low of $5.55.
Summary
Nuvectis's partner Haisco secured Breakthrough Therapy Designation from China's CDE for NXP200 in BRAF V600-mutant, recurrent or progressive high-grade glioma. This is the first regulatory milestone for NXP200 in China and validates the drug's clinical activity in a difficult-to-treat CNS tumor. The designation could expedite development and review in China, though Nuvectis's commercial rights are ex-Greater China. The company continues to advance NXP200 toward a U.S. IND submission in Q4 2026. This follows the July 2026 Chinese approval of ciprocopan (NXP100) for PNH, reinforcing the Haisco partnership's value.
Updates
· Wiseek News — Early data showed responses over 40%. U.S. IND filings for NXP200 and ciprocopan are targeted for Q4.
At the time of this announcement, NVCT was trading at $21.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $687.8M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.